A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer

PURPOSE: Preclinical data indicate that combination HER2-directed and anti-VEGF therapy may bypass resistance to trastuzumab. A phase I trial was performed to assess safety, activity, and correlates. EXPERIMENTAL DESIGN: Patients with advanced, refractory malignancy were enrolled (modified 3 + 3 des...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Invest New Drugs
Hauptverfasser: Falchook, Gerald S., Moulder, Stacy, Naing, Aung, Wheler, Jennifer J., Hong, David S., Piha-Paul, Sarina A., Tsimberidou, Apostolia M., Fu, Siqing, Zinner, Ralph, Janku, Filip, Jiang, Yunfang, Huang, Mei, Parkhurst, Kristin L., Kurzrock, Razelle
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2014
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4297242/
https://ncbi.nlm.nih.gov/pubmed/25323060
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0173-7
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge